<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02802423</url>
  </required_header>
  <id_info>
    <org_study_id>BLI-1401-2-01</org_study_id>
    <nct_id>NCT02802423</nct_id>
  </id_info>
  <brief_title>A Phase I/II, Open Label Study to Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Docetaxel Monotherapy in Patients With Advanced/Metastatic Triple Negative Breast Cancer (TNBC).</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioLite, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioLite, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine the safety and recommended dose level (RDL)
      of BLEX 404 Oral Liquid combined with Docetaxel monotherapy in a 21-day schedule. The
      secondary purpose is to assess the efficacy and safety of BLEX 404 Oral Liquid combined with
      Docetaxel monotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: Dose-limiting toxicity (DLT) observation</measure>
    <time_frame>3 weeks (1 cycle)</time_frame>
    <description>Presence or absence of dose-limiting toxicity (DLT) related to BLEX 404 Oral Liquid for each patient during first cycle of Docetaxel monotherapy to determine the recommended dose level (RDL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Overall response rate (PR + CR)</measure>
    <time_frame>12 weeks (4 cycles)</time_frame>
    <description>Overall response rate (PR + CR) after 4 cycles of combination use in BLEX 404 + Docetaxel monotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase II: Overall response rate (PR + CR)(at least 1 cycle)</measure>
    <time_frame>at least 3 weeks (1 cycle)</time_frame>
    <description>Overall response rate (PR + CR) after at least 1 cycle of combination use in BLEX 404 + Docetaxel monotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Incidence of grade 3/4 hematological toxicity</measure>
    <time_frame>3 weeks (1 cycle)</time_frame>
    <description>Rate of grade 3/4 hematological toxicity of each cycle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>3 weeks (1 cycle)</time_frame>
    <description>Examination of quality of life by EORTC QLQ-C30 questionnaire of each cycle.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Triple Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>BLEX 404 Oral Liquid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During Phase I study (dose escalation), a standard 3+3 design will be followed, and the dose range is 3 to 10 mg/kg BID. The recommended dose level (RDL) for the Phase II study is defined as the dose level with 0 to 1 DLT observed during cycle I of Docetaxel monotherapy among 6 patients in the Phase I study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BLEX 404 Oral Liquid</intervention_name>
    <description>BLEX 404 Oral Liquid is administered twice daily during the Docetaxel monotherapy period. The dose of Docetaxel is 75 mg/m2 IV, 21 days a cycle.</description>
    <arm_group_label>BLEX 404 Oral Liquid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Females aged 20 - 70 years old at the time of signing the ICF.

          2. Patients with histologically or pathologically diagnosed with advanced/metastatic
             triple negative (ER-, PR-, and HER2-negative) breast cancer.

               1. ER =&lt; 10% by immunohistochemistry (IHC) tumor staining;

               2. PR =&lt; 10% by IHC tumor staining;

               3. HER2-negative defined as one of the following: 0 or 1+ by IHC, or 2+ by IHC and
                  fluorescence in situ hybridization (FISH)-negative (ratio &lt; 2.0).

          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

          4. Adequate hematologic function defined as: absolute neutrophil count (ANC) greater than
             or equal to 2,000/μL; platelets count greater than or equal to 100,000/μL; hemoglobin
             must be greater than or equal to 10 g/dL (can be corrected by growth factor or
             transfusion).

          5. Adequate hepatic function defined as: serum bilirubin less than or equal to 1.5-fold
             upper limit of normal (ULN); aspartate aminotransferase (AST), alanine
             aminotransferase (ALT), and alkaline phosphatase (ALP) less than or equal to 3-fold
             ULN.

          6. Adequate renal function with: serum creatinine less than or equal to 1.3 mg/dL or
             calculated creatinine clearance greater than or equal to 60 mL/minute according to the
             Cockcroft and Gault formula.

          7. Women must be either of non-child bearing potential, or women with child-bearing
             potential agree to use effective a highly contraceptive method or a contraceptive
             implant, exception of hormonal contraception (estrogen/progesterone), from time of
             Screening Visit until 30 days after study drug discontinuation.

          8. Planning to receive Docetaxel monotherapy.

          9. Willing and able to comply with all aspects of the treatment protocol.

         10. Provide written informed consent.

        Exclusion Criteria:

          1. Patient with brain metastasis.

          2. Patient with autoimmune disease that requires systemic steroids or immunosuppression
             agents.

          3. Current enrollment in another clinical study or used any investigational drug or
             device within the past 28 days preceding informed consent.

          4. Patients with following treatment prior to Docetaxel monotherapy: chemotherapy,
             immunotherapy, or biologic systemic anticancer therapy within 21 days of study entry
             (42 days for mitomycin and nitrosoureas); prior taxanes; radiation therapy within 28
             days (3 months for bone marrow exposure 20%); hormonal therapy within 4 weeks.

          5. Known history of human immunodeficiency virus (HIV) infection.

          6. Existing anticancer treatment-related toxicities of Grades greater than or equal to 2
             (except for alopecia and neuropathy) according to Common Terminology Criteria for
             Adverse Events (CTCAE v4.03).

          7. Patients with Grade &gt; 2 neuropathy.

          8. Patient has an active infection requiring systemic therapy.

          9. History of concomitant medical conditions or infectious diseases that, in the opinion
             of the investigator, would compromise the subject's ability to safely complete the
             study.

         10. Clinically significant electrocardiogram (ECG) abnormality, including a marked
             baseline prolonged QT/QTc ([QT interval/corrected QT interval].

         11. Ascertained hypersensitivity to any component of investigational product used in the
             study.

         12. Uncontrolled nausea or vomiting or any symptom that would prevent the ability to
             comply with daily BLEX 404 Oral Liquid treatment.

         13. Judged to be not applicable to this study by investigator such as difficulty of
             follow-up observation, psychiatric disorder, with any other serious diseases/medical
             history.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gi-Ming Lai, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Municipal Wanfang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hsien-Ming Wu, Master</last_name>
    <phone>886-3-657-9631</phone>
    <phone_ext>13</phone_ext>
    <email>sonnywu@bioliteinc.com</email>
  </overall_contact>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2016</study_first_submitted>
  <study_first_submitted_qc>June 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2016</study_first_posted>
  <last_update_submitted>June 13, 2016</last_update_submitted>
  <last_update_submitted_qc>June 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TNBC</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>Triple negative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

